- ASSOCIATE CLINICAL PROFESSOR | Obstetrics, Gynecology and Reproductive Science
- Gynecologic Oncology
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Rahaman is an Associate Clinical Professor in the Division of Gynecologic Oncology. He has served as the Fellowship Program Director and the Director of the Gynecologic Oncology Chemotherapy Service at the Mount Sinai Medical Center. He has also previously served as the Division Director of Gynecologic Oncology at the Mount Sinai and Elmhurst Hospitals. He is one of a very few surgeons credentialed to teach and perform da Vinci Robotic surgery for Gynecologic cancers and near-Infrared fluorescence sentinel lymph node mapping. He established the Training Program in Robotic Surgery for Gynecologic Cancers and regained full accreditation for the Gynecologic Oncology Fellowship Program from ABOG during his tenure as Fellowship Director.
Dr. Rahaman received his medical training at The University of the West Indies and did his first Residency in Obstetrics and Gynecology at The Mount Hope Women's Hospital, in a Royal College of Obstetricians & Gynecologists Program. He also completed the full Residency in Obstetrics and Gynecology at The Mount Sinai Medical Center. In addition to the Fellowship training in Gynecologic Oncology at Mount Sinai, he also completed a two year Fellowship in Cardiac and Vascular surgery with Dr. Denton Cooley at the Texas Heart Institute. After serving as Chairman of The Department of Obstetrics & Gynecology at the Williamson ARH Hospital in Kentucky, he was recruited to return to the Faculty at Mount Sinai in the Division of Gynecologic Oncology.
Dr. Rahaman's academic responsibility focuses on the comprehensive training of subspecialty fellows in Gynecologic Oncology in addition to teaching resident physicians and medical students. He is widely recognized for his special expertise in complicated and challenging pelvic surgery especially laparoscopic, minimally invasive surgery and daVinci Robotic surgery. He is the Principal and co-investigator on several National & International Clinical trials for gynecologic cancers including GOG chemotherapy trials and HPV vaccination trials. Dr. Rahaman is also engaged in basic science and translational research to identify potential predictors of malignant transformation to ovarian cancers as well as investigating novel targets and pathways for emerging cancer therapeutic agents. He has authored numerous publications in International journals and written several book chapters in Gynecologic Oncology and has been the recipient of many teaching and peer recognition awards. His clinical practice encompasses the full spectrum of care for gynecologic cancers including Radical Surgery, Robotics, Argon Beam Laser, chemotherapy and biologic therapy. He is also a certified colposcopist for Cervical Dysplasia clinical trials and provides complete treatment for pre-invasive lower genital tract disease including laser therapy.
Mount Sinai Gynecologic Oncology Fellowship Program
Obstetrics & Gynecology
- Cancer Fatigue
- Cancer Pain Syndromes
- Cervical Cancer
- Cervical Conization
- Cervical Dysplasia
- Dilation And Curettage
- Endometrial Biopsy
- Exploratory Laparotomy
- Human Papillomavirus Testing
- Human Papillomavirus Vaccine
- Loop Electrosurgical Excision Procedure
- Lymph Node Biopsy
- Lysis Of Adhesions
- Ovarian Cancer
- Ovarian Cyst
- Ovarian Cyst Removal
- Robot-Assisted Laparoscopic Procedures
- Sentinel Lymph Node Biopsy
- Uterine Cancer
- Uterine Fibroids
- Vaginal Cancer
Cancer, Cancer Genetics, Genomics, Molecular Biology, Oncogenes, Positron Emission Tomography, Tumor Suppressor Genes
MD, University of the West Indies
Residency, Obs/ Gyn
Mount Hope Women's Hospital
Residency, Obs/ Gyn
Lincoln Medical & Mental Health Ct.
Residency, Obs/ Gyn
Mount Sinai Hospital
Fellowship, Cardio & Vascular
Texas Heart Institute
Fellowship, Gynecology Oncology
Mount Sinai Hospital
Sydney Druce Award
Department of Obstetrics & Gynecology at Mount Sinai
Marquis-Who's Who in America
Best Doctors in New York
New York Magazine
New York Times
Biltmore Who's Who
US News & World Report
Top Minimal Invasive Surgeons
New York Magazine
ACOG Annual Meeting Film Festival
Laparoscopic Staging in Patient with Fallopian Tube Carcinoma
Top Doctors in New York Metro Area
Castle Conolly Medical
CREOG/ACOG National Faculty Teaching Award for Residency Education
Resident of the Year Award
Lincoln Medical Center
Leonard de Cordova Medal in Physiology
Noel Haye Prize in Anatomy
Class Prize in Internal Medicine
University of the West Indies Open Scholarship
Trinidad and Tobago National Scholarship
Active Clinical Trials
GOG0218 A Phase III Trial of Carboplatin and Paclitaxel plus placebo versus Carboplatin and Paclitaxel plus concurrent Bevacizumab (NSC # 704865, IND #7921) followed by placebo, versus Carboplatin and Paclitaxel plus concurrent and extended Bevacizumab, in women who are newly diagnosed, previously untreated, Stage III or IV, epithelial overian or primary peritoneal cancer NCI-supplied agent(s): Bevacizumab/Placebo (NSC #704865, IND #7921)
GOG0213 A Phase III randomized controlled clinical trial of Carboplatin and Paclitazel alone or in combination with Bevacizumab (NSC #704865, IND #7921) followed by Bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritone primary and fallopian tube cancer. NCI-supplied agents: Bevacizumab (NSC #704865, IND #7921)
GOG0212 A randomized phase III trial of maintenance chemotherapy comparing 12, monthly cycles of single agent Paclitaxel or CT-2103 (IND #70177), versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer achieve a complete clinical response to primary platinum/taxane chemotherapy
GOG0209 A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
GOG0210 A Molecular Staging Study of Endometrial Carcinoma
GOG0233 / ACRIN 6671 Utility of preoperative FDG-PET/CT and Ferumoxtran-10 MRI scanning prior to primary chemoradiation therapy to detect retroperitoneal lymph node metastasis in patients with locoregionally advanced (IB2, IIA ≥4 CM, IIB-IVA) carcinoma of the cervix
GOG0215 A Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk-Reducing Surgery that Results in Removal of Both Ovaries
GOG0136 Acquisition of human gynecologic specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer
GCO# 06-0832 Investigator Initiated Phase I/II trial of combination intra-peritoneal Docetaxel and intravenous pegylated liposomal doxorubicin in persistent epithelial ovarian, peritoneal and fallopian tube carcinoma.
GCO # 04-0754 A Phase lll, Double-Blind, Randomized, Controlled, Multi-Center, Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals ' HPV-16/18 VLP/AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age
GCO # 07-0267 A Phase lllb, Observer-Blind, Randomized, Multicenter Study With Two Parallel Groups to Compare the Immunogenicity of GlaxoSmithKline Biological 's HPV-16/18 L 1/AS04 Vaccine Versus Merck 's Gardasil Vaccine When Administered Intramuscularly According to a 3-DoseSchedule in Healthy Adult Females 18-45 Years of Age
Protocol 108933 (HPV-010)
- KLF6 is a novel regulator of VEGF in Ovarian cancer cell lines.
- Utility of a novel microarray assessment of critical signaling pathways in ovarian cancer
- MicroRNA signatures in Human Ovarian cancer and response to chemotherapy.
- Comparative Genomic Hypridiztion (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma.
- Combination anti-estrogen and proteosome inhibitor biologic therapy for uterine cancer.
Carboplatin & Paclitaxel Alone or in Combo w/Bevacizumab (ovarian cancer)
One purpose of this study is to compare the combination of carboplatin, paclitaxel and bevacizumab to the standard combination of carboplatin and paclitaxel alone. A second purpose of this study is to determine if a second surgery to remove tumor followed by chemotherapy can incr...
Zakashansky K, Chuang L, Gretz HF, Nagarsheth N, Rahaman J, Nezhat FN. A case controlled study of total laparoscopic radical hysterectomy with pelvic lymphadenectomy versus radical abdominal hysterectomy in a fellowship training program. Int J Gynecol Cancer 2007 Mar 26; [Epub ahead of print] .
Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman J, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Fallopian Tube and Primary Peritoneal Carcinoma Associated with BRCA Mutation. J Clin Oncol 2003; 21.
Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, DiFeo A. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature communications 2014; 5.
Kolev V, Pereira EB, Schwartz M, Sarpel U, Roayaie S, Labow D, Momeni M, Chuang L, Dottino P, Rahaman J, Zakashansky K. The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2014 Jan; 24(1).
Cardenas-Goicoechea J, Shepherd A, Momeni M, Mandeli J, Chuang L, Gretz H, Fishman D, Rahaman J, Randall T. Survival analysis of robotic versus traditional laparoscopic surgical staging for endometrial cancer. American journal of obstetrics and gynecology 2014 Feb; 210(2).
Momeni M, Kolev V, Cardenas-Goicoechea J, Getrajdman J, Fishman D, Chuang L, Kalir T, Rahaman J, Zakashansky K. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens?. American journal of obstetrics and gynecology 2013 Jan; 208(1).
Kinoshita Y, Kalir T, Rahaman J, Dottino P, Kohtz DS. Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. The American journal of pathology 2012 Jan; 180(1).
Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics : a review publication of the Radiological Society of North America, Inc; 31(2).
Son H, Kositwattanarerk A, Hayes MP, Chuang L, Rahaman J, Heiba S, Machac J, Zakashansky K, Kostakoglu L. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics : a review publication of the Radiological Society of North America, Inc 2010 Sep; 30(5).
Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H. Chemotherapy for gynecologic cancers. The Mount Sinai journal of medicine, New York 2009 Dec; 76(6).
Zakashansky K, Bradley WH, Chuang L, Rahaman J, Dottino P. Recent advances in the surgical management of cervical cancer. The Mount Sinai journal of medicine, New York 2009 Dec; 76(6).
Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. American journal of obstetrics and gynecology 2009 Jan; 200(1).
Gretz H, Bradley WH, Zakashansky K, Nezhat F, Rahaman J, Chuang L, Bohren DL, Kreiger K, Rubin E, Sokolow A. Patient clinical factors influencing use of hysterectomy in New York, 2001-2005. American journal of obstetrics and gynecology 2008 Oct; 199(4).
Chuang LT, Moqattash ST, Gretz HF, Nezhat F, Rahaman J, Chiao JW. Sulforaphane induces growth arrest and apoptosis in human ovarian cancer cells. Acta obstetricia et gynecologica Scandinavica 2007 Oct; 86(10).
Bradley WH, Dottino PR, Rahaman J. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society; 18(6).
Nagarsheth NP, Harrison M, Kalir T, Rahaman J. Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society; 16(3).
Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE. Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Archives of pathology & laboratory medicine 2005 May; 129(5).
Nagarsheth NP, Kalir T, Rahaman J. Post-transplant lymphoproliferative disorder of the cervix. Gynecologic oncology 2005 Apr; 97(1).
Argenta PA, Rahaman J, Gretz HF, Nezhat F, Cohen CJ. Vacuum-assisted closure in the treatment of complex gynecologic wound failures. Obstetrics and gynecology 2002 Mar; 99(3).
Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecologic oncology 2014 Sep; 134(3).
Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecologic oncology 2004 Apr; 93(1).
Alvarez RD, Gray HJ, Timmins PF, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. Gynecologic oncology 2013 Apr; 129(1).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Rahaman did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.